9 Real-world Treatment Patterns and Clinical Outcomes in Patients Treated With Eribulin After Prior Immunotherapy (IO) or Antibody-Drug Conjugate (ADC) for Metastatic Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement39th Annual Miami Breast Cancer Conference® - Abstracts
Volume 36
Issue suppl 3
Pages: 13

Background

Eribulin was FDA approved in 2010 for the treatment of metastatic breast cancer (mBC) in the United States. Recently, several immunotherapy (IO) regimens and an antibody-drug conjugate (ADC) have been FDA approved for patients with triple-negative breast cancer (TNBC). This study aimed to assess the treatment patterns and clinical outcomes in patients with mBC treated with eribulin following either IO or ADC therapy in US clinical practice.


Methods

A retrospective, noninterventional patient medical chart review study was conducted. Consenting oncologists provided deidentified patient data via an electronic case report form. Adult female patients diagnosed with mBC and who began treatment with eribulin between March 1, 2019, and September 30, 2020, following prior therapy with an IO (atezolizumab [Tecentriq]) or ADC (sacituzumab govitecan [Trodelvy]) were included. Eribulin treatment characteristics were recorded. Overall survival (OS) since eribulin initiation was assessed using Kaplan-Meier methods.


Results

This analysis included 91 eligible patients, of whom 53 received prior atezolizumab, and 38 had prior sacituzumab govitecan. Patients’ median age was 63 years at eribulin treatment initiation, and 57% were Caucasian. The majority of eribulin-treated patients had TNBC (74.7%); 13.2% had hormone receptor–positive/HER2-negative disease. In the study cohort, eribulin was classified as second-line, third-line, and fourth- or later-line in 76%, 13%, and 11% of patients, respectively, in regard to line of therapy in the metastatic setting. At last follow-up, eribulin treatment was ongoing for 36.3% of patients. The median treatment duration was 5.1 months (q1, q3: 3.5-7.3) among those who had discontinued eribulin, and 12.2 months (q1, q3, 11-14) among those who were still on treatment. At last follow-up, 63.7% of patients were alive. Median was not reached for OS subsequent to initiation of eribulin. The estimated OS rates at 12 and 24 months were 77.8% (95% CI, 67.3%-85.3%) and 53.6% (95% CI, 35.1%-68.9%), respectively.


Conclusion

Among patients with mBC who initiated eribulin following an IO or ADC, more than 50% were estimated to be alive after 2 years. Eribulin may be a promising treatment option for patients for whom IO or ADC failed.

Author Affiliations:

Ravi K. Goyal,1 Jingchuan Zhang,2 Samina Dhuliawala,1 Martina Sluga-O’Callaghan,1 Peter A. Kaufman3

1RTI Health Solutions, Research Triangle Park, NC

2Eisai Inc, Nutley, NJ

3Larner College of Medicine, Division of Hematology/ Oncology, University of Vermont Cancer Center, Burlington, VT

Articles in this issue

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients  in a Breast Cancer Registry
15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy  and Symptoms
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
Related Content